In addition,
new small molecule drugs are being used that target important survival pathways in NHL tumor cells.
Not exact matches
The
new research, published recently as two separate studies in ACS Central Science and the Journal of the American Chemical Society, demonstrates that a
new class of
drugs called
small molecule RNA inhibitors can successfully target and kill specific types of cancer.
The researchers created a
new gel, based on
small molecules which self - assemble into nanofibers which could interact with a variety of anti-inflammatory, painkiller
drugs, including iburofen and naproxen.
Nanotechnology has unlocked
new pathways for targeted
drug delivery, including the use of nanocarriers, or capsules, that can transport cargoes of
small -
molecule therapeutics to specific locations in the body.
The researchers behind the
new study, from Winston - Salem State University in the US and Universiti Malaysia Sarawak in Malaysia, have found that adding similar, but
smaller polycationic
molecules onto a
new kind of material called carbon nanodots makes them even better at killing
drug - resistant bacteria.
The
new drug, a
small molecule called anle138b, blocks these pores from moving ions in and out of nerve cells.
An international team of researchers has shown that a
new small -
molecule drug can restore brain function and memory in a mouse model of Alzheimer's disease.
The researchers tested two anti-CK2
drugs for their ability to stimulate the production of
new brown fat in mice: a
new small -
molecule CK2 - blocker called silmitasertib (CX - 4945), which is already in clinical trials as a cancer therapeutic; and a more precise next - generation antisense oligonucleotide (ASO)
drug developed in collaboration with Isis Pharmaceuticals, which eliminates CK2 by blocking the RNA instructions cells use to produce it.
As a postdoctoral researcher at Harvard Medical School, he investigated the use of
small -
molecule drugs to manipulate signaling pathways to enable otherwise senescent progenitor cells of the cochlea to divide and form
new sensory cells.
The
new method gives scientists more power not only to find
new antibody - based therapies, but also to discover the biological pathways through which they work — pathways that may turn out to be more easily and cheaply targeted by
small -
molecule drugs.
A
new class of experimental
drug - like
small molecules is showing great promise in targeting a brain enzyme to prevent early memory loss in Alzheimer's disease, according to Northwestern Medicine ® research.
Efforts to inhibit this enzyme, called β - secretase 1 (BACE1), with
small molecule drugs have met with limited success so far, says Ryan Watts, a neurobiologist at the biotech company Genentech in South San Francisco, California, and one of the leaders of the
new research.
The initiative will also allow the CMI to foster
new partnerships between academia and industry, and utilize the individual strengths that each possess to expedite the early stages of
small molecule drug discovery.
Using the
new method, published on July 31, 2017 in Nature Chemistry, the TSRI scientists identified more than 100 human proteins that are likely to be targetable with
small molecule, pill - based
drugs.
Small -
molecule antagonists of CCR5 and CXCR4: a promising
new class of anti-HIV-1
drugs.
Not a light read, this tome is bursting with information about monoclonal antibodies, from the history of how these therapies were first developed to
new approaches such as conjugate therapy, which combines antibodies with
small -
molecule drugs.
«This partnership puts our mRNA Therapeutics platform in the hands of Karolinska's world - class scientists and clinical researchers to develop
new drugs and therapeutic approaches that can not be done with
small molecules or biologics — bringing
new hope to patients with serious diseases.»
Vescor, advised by its scientific founders White and Kimmelman, whose research has shown inhibition of autophagy can dramatically impact tumor growth in pre-clinical models, will develop
small molecule inhibitors of a number of protein targets at critical nodes of the autophagy cascade, perform investigational
new drug (IND) enabling studies, and move these into clinical development.
MIT's
new nanoparticle carries three cancer - fighting
drug molecules — doxorubicin is red, the
small green particles are camptothecin, and the larger green core contains cisplatin (Image: Jeremiah Johnson)
Orders of magnitude more sensitive than conventional Raman microscopy, they allow mapping of 3D distributions of
small molecules, such as metabolites and
drugs, as well as tumor identification in tissues, which open many exciting
new possibilities for biology and medicine.
Then for postdoctoral research I moved to Yale University, where I worked in a lab that looked at all kinds of different disease areas using the approaches of a field called chemical biology, which is using
small molecules — chemicals — to probe biological systems in the hopes of developing compounds that could be
new drugs.
Reykjavik, ICELAND, January 13, 2005 — deCODE genetics (Nasdaq: DCGN) has submitted an investigational
new drug application (IND) to the U.S. Food and Drug Administration (FDA) for DG041, a novel, first - in - class, orally - administered small molecule for the treatment o
drug application (IND) to the U.S. Food and
Drug Administration (FDA) for DG041, a novel, first - in - class, orally - administered small molecule for the treatment o
Drug Administration (FDA) for DG041, a novel, first - in - class, orally - administered
small molecule for the treatment of...
Published June 25, 2015 in Molecular Cell, the
new study identifies a
small molecule drug that specifically blocked the first step of autophagy, effectively cutting off the recycled nutrients that cancer cells need to live.
eFFECTOR is pioneering a
new class of
small molecule drugs that act by selectively regulating translation, also known as protein synthesis.
As part of the global effort toward malaria eradication, phenotypic whole - cell screening revealed the 2 - aminopyridine class of
small molecules as a good starting point to develop
new antimalarial
drugs.
I am interested in Scientist position for designing and developing novel
small molecules, developing
new synthetic routes and process optimization, for
drug discovery and development.